The estimated Net Worth of Kenneth I Moch is at least $795 Thousand dollars as of 13 June 2023. Mr. Moch owns over 115 units of Zynerba Pharmaceuticals Inc stock worth over $98,511 and over the last 11 years he sold ZYNE stock worth over $695,996. In addition, he makes $0 as Independent Director at Zynerba Pharmaceuticals Inc.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Sign up
Mr. Moch ZYNE stock SEC Form 4 insiders trading
Kenneth has made over 5 trades of the Zynerba Pharmaceuticals Inc stock since 2014, according to the Form 4 filled with the SEC. Most recently he sold 115 units of ZYNE stock worth $40 on 13 June 2023.
The largest trade he's ever made was selling 18,979 units of Zynerba Pharmaceuticals Inc stock on 13 March 2014 worth over $474,475. On average, Kenneth trades about 1,038 units every 114 days since 2013. As of 13 June 2023 he still owns at least 75,778 units of Zynerba Pharmaceuticals Inc stock.
You can see the complete history of Mr. Moch stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Kenneth Moch biography
Kenneth I. Moch serves as Independent Director of the Company. Mr. Moch has more than 35 years of experience in managing and financing biomedical technologies, and has played a key role in building five life science companies. Since October 2016, Mr. Moch has served as the president and chief executive officer of Cognition Therapeutics, Inc. He previously was the managing partner of The Salutramed Group, LLC, from September 2015 until October 2016, where he provided strategic and tactical counsel to the biotechnology and pharmaceutical industries. Prior to that, he served as president of Euclidian Life Sciences Advisors, a strategic advisory firm for life sciences companies, from April 2014 until September 2015. From April 2010 to April 2014, he served as president and chief executive officer, and as a director, of Chimerix, Inc., having joined the company as chief operating officer in June 2009. Previously, he was president and chief executive officer of three life science companies—BioMedical Enterprises, Inc., Alteon, Inc., and Biocyte Corporation—and was a co-founder and vice president of The Liposome Company, Inc. He also served as managing director of Healthcare Investment Banking at ThinkEquity Partners and as a management consultant with McKinsey & Company. Mr. Moch has served as a director of Gamida Cell, Ltd, a biopharmaceutical company since September 2016. In the public policy arena, Mr. Moch currently is a member of the board of the Biotechnology Innovation Organization, serving as chair of the Bioethics Committee, and previously served as chairman of BioNJ. Mr. Moch holds an A.B. in Biochemistry from Princeton University and an M.B.A. with emphasis in Finance and Marketing from the Stanford Graduate School of Business. With more than 25 years of experience in the biomedical technology and pharmaceutical industries, Mr. Moch brings valuable expertise in biomedical technology company leadership and financing matters to our Board.
How old is Kenneth Moch?
Kenneth Moch is 65, he's been the Independent Director of Zynerba Pharmaceuticals Inc since 2015. There are 2 older and 12 younger executives at Zynerba Pharmaceuticals Inc. The oldest executive at Zynerba Pharmaceuticals Inc is Daniel Kisner, 72, who is the Independent Director.
What's Kenneth Moch's mailing address?
Kenneth's mailing address filed with the SEC is C/O GAMIDA CELL LTD., 116 HUNTINGTON AVENUE, BOSTON, MA, 02116.
Insiders trading at Zynerba Pharmaceuticals Inc
Over the last 9 years, insiders at Zynerba Pharmaceuticals Inc have traded over $154,101 worth of Zynerba Pharmaceuticals Inc stock and bought 224,703 units worth $2,383,877 . The most active insiders traders include John P. Butler, William J Federici, and Michael Rapp. On average, Zynerba Pharmaceuticals Inc executives and independent directors trade stock every 69 days with the average trade being worth of $12,515. The most recent stock trade was executed by Terri B Sebree on 12 September 2023, trading 12,401 units of ZYNE stock currently worth $16,493.
What does Zynerba Pharmaceuticals Inc do?
at zynerba pharmaceuticals (nasdaq: zyne), we are dedicated to developing next-generation synthetic cannabinoid therapeutics for transdermal delivery for patients with significant unmet medical needs. our mission is to improve the lives of patients battling severe health conditions including refractory epilepsy, osteoarthritis, fragile x syndrome, fibromyalgia and peripheral neuropathic pain through these therapeutics. our development pipeline includes patent-protected synthetic transdermal cannabinoid products, cbd gel – zyn002 and thc pro-drug patch – zyn001, which we believe will provide new treatment options for patients as well as additional treatment options for patients not currently receiving adequate relief or otherwise experiencing intolerable side effects from current treatment regimes.
What does Zynerba Pharmaceuticals Inc's logo look like?
Complete history of Mr. Moch stock trades at Chimerix Inc, Zynerba Pharmaceuticals Inc, and Gamida Cell Ltd
Zynerba Pharmaceuticals Inc executives and stock owners
Zynerba Pharmaceuticals Inc executives and other stock owners filed with the SEC include:
-
Armando Anido,
Chairman of the Board, Chief Executive Officer -
Terri Sebree,
President -
Armando Anido MBA,
Chairman & CEO -
James Fickenscher,
Chief Financial Officer, Vice President - Corporate Development -
Terri B. Sebree,
Pres -
James E. Fickenscher,
CFO, VP of Corp. Devel. & Treasurer -
Suzanne Hanlon,
Vice President, General Counsel, Secretary -
William Roberts,
Vice President, Investor Relations and Corporate Communications -
Pamela Stephenson,
Independent Director -
Kenneth Moch,
Independent Director -
Daniel Kisner,
Independent Director -
William Federici,
Independent Director -
John Butler,
Independent Director -
Warren Cooper,
Lead Independent Director -
Brian Rosenberger,
Vice President - Commercial and Business Development -
Joseph Apostolico,
VP of HR -
Suzanne M. Hanlon,
Sec., VP & Gen. Counsel -
Dr. Joseph Palumbo,
Chief Medical Officer -
Thomas L Harrison,
Director -
Michael Rapp,
10% owner -
Cynthia Ann Rask,
Director -
Albert P Parker,
Chief Legal Officer -
Richard A Baron,
Chief Financial Officer -
Kenneth T Jones,
See Remarks